(inspiring music plays)
-: Peter, we learned a lot about different
cell and gene therapy from the COVID vaccine efforts.
What other lessons are you taking away from this?
-: So, thanks.
I think there were probably two.
One is that early and often communication
with the agency on products really helps.
I mean, that is what helped with vaccines, cell therapies,
even convalescent plasma. All of those things
where we had a dialogue that happened in near real time
made a big difference on avoiding issues in manufacturing,
clinical development,
and it really helped those products move forward quickly.
Now there's obviously a challenge
in sustaining the staff needed to do that,
but I think in the gene therapy area,
it's really critical that we do so,
because I think that could make the difference between
really having us bolt forward, leap forward quickly,
or kind of remain at kind of a crawling pace forward.